Effectiveness of Pfizer’s RSV vaccine could reduce disease burden in older adults
The bivalent respiratory syncytial virus prefusion F, or RSVpreF, vaccine may prevent one hospitalization or ED visit tied to the infection for every 250 vaccinated older adults, an analysis showed.The data are consistent with recent findings on respiratory syncytial virus (RSV) vaccine effectiveness and suggest the opportunity “to reduce severe medically attended RSV disease burden,”